OPEN STUDY, MULTICENTER, CONTROLLED OF EXEMESTANE (AROMASIN) WITH OR WITHOUT CELECOXIB (CELEBREX) IN POSTMENOPAUSIC WOMEN WITH ADVANCED BREAST CANCER (CAM) THAT HAS PROGRESSED DESPITE TAMOXIFE

Not Applicable

• Conditions: -C50 Malignant neoplasm of breast; Malignant neoplasm of breast; C50

• Registration Number: PER-025-02
• Lead Sponsor: PHARMACIA & UPJOHN INTERAMERICAN CORPORATION,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2002-03-13
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1) Patients postmenopausal women with breast cancer confirmed histologically or cytologically.
2) Advanced disease: patients with advanced breast carcinoma with progression of disease who have progressed / relapsed after> 8 weeks of treatment with Tamoxifen for advanced disease.
3)> 3 weeks from the last chemotherapy and> 4 weeks since the last radiotherapy.
4) Recovery of all acute toxicities by previous treatment (except alopecia), and of any major surgery.

Exclusion Criteria

1) More than one previous chemotherapy and / or more than one hormone therapy for advanced disease.
2) Hormonotherapy for advanced disease other than Tamoxifen.
3) Any other concomitant anticancer treatment.
4) Previous use (within 4 weeks of the start of treatment) or concomitant hormone replacement therapy or progestogen therapy.
5) Use of LH / RH agonists in the three months prior to the start of treatment.
6) Presence of brain metastasis, compression of the spinal cord or carcinomatous meningitis.
7) Other concomitant malignancies

Study & Design

• Study Type: Interventional
• Study Design: Not specified